Advanced Filter

Filter by Group

Filter by Market Availability

Did you mean 2536 71 8?
Displaying drugs 1201 - 1225 of 1916 in total
NNZ-2591 (cyclo-L-glycyl-L-2-allylproline) is an investigational synthetic analog of cyclic glycine-proline (cGP), a breakdown product of human insulin-like growth factor 1 (IGF-1), that has been chemically modified to increase its half-life, stability, and oral bioavailability. It is currently under development by Neuren Pharmaceuticals for the symptomatic treatment of Angelman, Phelan-McDermid, and...
Investigational
Azosemide is a loop diuretic used to treat hypertension, edema, and ascites.
Investigational
AVP-21D9 is a fully human anthrax monoclonal antibody that is being investigated as an anthrax antitoxin.
Investigational
Ty800 is a vaccine designed to offer rapid, oral, single-dose protection against Salmonella typhi, the cause of typhoid fever. The Ty800 vaccine was developed using genetic techniques to delete specific genes known to be essential to the virulence of S. typhi. It is being developed by AVANT Immunotherapeutics, Inc.
Investigational
XL820 is investigated for use/treatment in solid tumors. XL820 is a solid. The proteins that XL820 inhibit include platelet-derived growth factor receptor beta (PDGFR), mast/stem cell growth factor receptor KIT, vascular endothelial growth factor receptor 2, and platelet-derived growth factor receptor alpha, clinically validated targets implicated in a variety of...
Investigational
Experimental
Investigational
PT886 is a bispecific antibody against Claudin 18.2 and cluster of differentiation 47 (CD47)
Investigational
Experimental
AZD-8165 is under investigation in clinical trial NCT01150812 (Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects).
Investigational
ARCT-810 is an mRNA replacement therapy that delivers ornithine transcarbamylase mRNA to hepatocytes.
Investigational
Investigational
Investigational
Tetrathiomolybdate is an oral, small-molecule, anticopper agent that is highly specific for lowering the levels of free copper in serum. COPREXA has completed pivotal clinical trials for the treatment of neurologic Wilson's disease. It is also developed for fibrotic disorders based upon the rationale that the fibrotic disease process is...
Investigational
Experimental
Experimental
XL844 is investigated for the use and treatment solid tumors. XL844 is a solid. XL844 is a potent inhibitor of the checkpoint kinases CHK1 and CHK2, which induce cell cycle arrest in response to a variety of DNA damaging agents. Known drug targets of XL844 including serine/threonine-protein kinase Chk1 and...
Investigational
VCA-894A is a synthetic 2'-O-methoxyethyl phosphorothioate oligoribonucleotide sodium salt consisting of 19 nucleotide residues with the sequence 5'-MeCMeUGMeUGGAAGMeUGAGGGMeCMeCAG-3'
Investigational
Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder of episodic, progressive heterotropic ossification. FOP is characterized by episodic inflammatory episodes, which may be precipitated by trauma, including immunizations and minor tissue damage, which usually result in ossification of the lesion. Patients experience abnormal cartilage formation, growth plate dysplasia,...
Investigational
Experimental
Matched Mixtures name: … TILIDIN 100/8 RETARD 1A PH ... TILIDIN 100/8 RETARD 1A PH ... TILIDIN 100/8 RETARD 1A PH …
Icariin has been investigated for the basic science of the Pharmacokinetic Profile of Icariin in Humans.
Investigational
Matched Iupac: … 5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-7-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl …
TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders. TTP889 is the only known selective small molecule inhibitor of Factor IX, a key enzyme of the intrinsic pathway of the blood coagulation system. TTP889 has proven...
Investigational
PHE885 is an investigational, autologous B-cell Maturation Antigen (BCMA)-directed chimeric antigen receptor (CAR)-T cell therapy.
Investigational
BBM-H803 is a recombinant adeno-associated virus (AAV) based gene therapy drug for hemophilia A developed and manufactured by Belief BioMed. It consists of an adeno-associated virus vector containing an expression cassette of the human Factor VIII transgene.
Investigational
Displaying drugs 1201 - 1225 of 1916 in total